Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Aug;148(5):394-404.
doi: 10.1161/CIRCULATIONAHA.122.062517. Epub 2023 May 25.

Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry

Sarah Abou Alaiwi  1 , Thomas M Roston  1   2 , Peter Marstrand  3 , Brian Lee Claggett  1 , Victoria N Parikh  4 , Adam S Helms  5 , Jodie Ingles  6 , Rachel Lampert  7 , Neal K Lakdawala  1 , Michelle Michels  8 , Anjali T Owens  9 , Joseph W Rossano  10 , Sara Saberi  5 , Dominic J Abrams  11 , Euan A Ashley  4 , Christopher Semsarian  12 , John C Stendahl  7 , James S Ware  13 , Erin Miller  14   15 , Thomas D Ryan  14   15 , Mark W Russell  5 , Sharlene M Day  9 , Iacopo Olivotto  16 , Christoffer R Vissing #  17 , Carolyn Y Ho #  1
Affiliations
Multicenter Study

Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry

Sarah Abou Alaiwi et al. Circulation. 2023 Aug.

Abstract

Background: The development of left ventricular systolic dysfunction (LVSD) in hypertrophic cardiomyopathy (HCM) is rare but serious and associated with poor outcomes in adults. Little is known about the prevalence, predictors, and prognosis of LVSD in patients diagnosed with HCM as children.

Methods: Data from patients with HCM in the international, multicenter SHaRe (Sarcomeric Human Cardiomyopathy Registry) were analyzed. LVSD was defined as left ventricular ejection fraction <50% on echocardiographic reports. Prognosis was assessed by a composite of death, cardiac transplantation, and left ventricular assist device implantation. Predictors of developing incident LVSD and subsequent prognosis with LVSD were assessed using Cox proportional hazards models.

Results: We studied 1010 patients diagnosed with HCM during childhood (<18 years of age) and compared them with 6741 patients with HCM diagnosed as adults. In the pediatric HCM cohort, median age at HCM diagnosis was 12.7 years (interquartile range, 8.0-15.3), and 393 (36%) patients were female. At initial SHaRe site evaluation, 56 (5.5%) patients with childhood-diagnosed HCM had prevalent LVSD, and 92 (9.1%) developed incident LVSD during a median follow-up of 5.5 years. Overall LVSD prevalence was 14.7% compared with 8.7% in patients with adult-diagnosed HCM. Median age at incident LVSD was 32.6 years (interquartile range, 21.3-41.6) for the pediatric cohort and 57.2 years (interquartile range, 47.3-66.5) for the adult cohort. Predictors of developing incident LVSD in childhood-diagnosed HCM included age <12 years at HCM diagnosis (hazard ratio [HR], 1.72 [CI, 1.13-2.62), male sex (HR, 3.1 [CI, 1.88-5.2), carrying a pathogenic sarcomere variant (HR, 2.19 [CI, 1.08-4.4]), previous septal reduction therapy (HR, 2.34 [CI, 1.42-3.9]), and lower initial left ventricular ejection fraction (HR, 1.53 [CI, 1.38-1.69] per 5% decrease). Forty percent of patients with LVSD and HCM diagnosed during childhood met the composite outcome, with higher rates in female participants (HR, 2.60 [CI, 1.41-4.78]) and patients with a left ventricular ejection fraction <35% (HR, 3.76 [2.16-6.52]).

Conclusions: Patients with childhood-diagnosed HCM have a significantly higher lifetime risk of developing LVSD, and LVSD emerges earlier than for patients with adult-diagnosed HCM. Regardless of age at diagnosis with HCM or LVSD, the prognosis with LVSD is poor, warranting careful surveillance for LVSD, especially as children with HCM transition to adult care.

Keywords: cardiomyopathies; cardiomyopathy, hypertrophic; genetics; heart failure; ventricular dysfunction.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Ho is a consultant for and receives research funding from Bristol Myers Squib, Pfizer, Cytokinetics, Tenaya, and BioMarin. Dr Parikh receives research funding from BioMarin and consults for Nuevocor and Viz.ai. Dr Lakdawala is a consultant for Bristol Myers Squibb, Pfizer, Cytokinetics, Tenaya, and Sarepta, and receives research funding from Pfizer. Drs Saberi and Michels are consultants for Bristol Myers Squibb and Cytokinetics. Dr Claggett has received personal fees from Amgen, Cardurion, Corvia, Cytokinetics, Intellia, and Novartis outside the submitted work. Dr Ashley is a co-founder of Deepcell, Personalis, and SVEXA, a board member of AstraZeneca, and an adviser to Apple, Foresite Labs, Nuevocor, and Sequencebio. Dr Lampert has received research funding and honoraria from Medtronic and Abbott, honoraria from Boston Scientific, and sat on advisory board for Medtronic. Dr Olivotto is a consultant for or receives research grants from: BMS-Myokardia, Cytokinetics, Boston Scientific, Sanofi Genzyme, Shire Takeda, Amicus, Menarini International, Bayer, and Tenaya. Dr Helms receives research funding from Bristol Myers Squibb and is a consultant for Tenaya and Lexeo Therapeutics. Dr Ingles receives research grant support from Bristol Myers Squibb. Dr Rossano is a consultant for Merck, Bayer, Bristol Myers Squibb, BioMarin, and CRI Biotech. Dr Ware has consulted for MyoKardia (now Bristol Myers Squibb), Foresite Labs, and Pfizer. Dr Abrams is a consultant for Dinaqor. Dr Marstrand has been employed at Novo Nordisk A/S. Novo Nordisk A/S was not involved in this research, and the views presented do not necessarily reflect the views of Novo Nordisk A/S. Drs Alaiwi, Roston, Semsarian, Stendahl, Ryan, Russell, Miller, and Vissing declare no relevant disclosures or competing interests.

Figures

Figure 1.
Figure 1.
Cumulative incidence of left ventricular systolic dysfunction in patients with childhood-diagnosed hypertrophic cardiomyopathy. Cumulative incidence of left ventricular systolic dysfunction (LVSD) in patients with childhood-diagnosed hypertrophic cardiomyopathy (HCM) from time (in years) since initial SHaRe (Sarcomeric Human Cardiomyopathy Registry) evaluation (A), time (in years) since diagnosis with HCM (B), and birth (age in years; C). Of the 954 patients with childhood-diagnosed HCM and no left ventricular systolic dysfunction at initial SHaRe visit, 59 patients did not have follow-up.
Figure 2.
Figure 2.
Predictors of developing incident left ventricular systolic dysfunction in patients with childhood-diagnosed hypertrophic cardiomyopathy, from the time of first SHaRe Registry evaluation. Patients with prevalent left ventricular systolic dysfunction (LVSD) or with missing values on left ventricular ejection fraction (LVEF) at initial evaluation were excluded. Results are reported from a multiple Cox proportional hazards model. HCM indicates hypertrophic cardiomyopathy; P/LP, pathogenic or likely pathogenic; SHaRe, Sarcomeric Human Cardiomyopathy Registry; and VUS, variant of unknown significance.
Figure 3.
Figure 3.
Cumulative and age-specific incidence of major adverse outcomes in patients with childhood-diagnosed hypertrophic cardiomyopathy stratified by the presence of left ventricular systolic dysfunction. A, Cumulative incidence of death, cardiac transplantation (Txp), or left ventricular assist device (LVAD) implantation in patients with childhood diagnosis of hypertrophic cardiomyopathy and left ventricular systolic dysfunction (LVSD). B, Age-specific incidence of death, Txp, or LVAD implantation in patients with childhood-diagnosed hypertrophic cardiomyopathy stratified by the presence of LVSD. The error bars denote the 95% CIs, and the groups have been slightly offset in the horizontal plane to avoid overlap.
Figure 4.
Figure 4.
Predictors of the primary outcome of death, cardiac transplantation, or left ventricular assist device implantation in patients with childhood-diagnosed hypertrophic cardiomyopathy who develop left ventricular systolic dysfunction. Results are reported from a multiple Cox proportional hazards model, in which age was used as the time scale with left-truncation at time of left ventricular systolic dysfunction. LVAD indicates left ventricular assist device; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; Txp, cardiac transplantation; and VUS, variant of unknown significance.
Figure 5.
Figure 5.
Cumulative incidence of the composite outcome of death, cardiac transplant, or left ventricular device implantation from time of clinical recognition of left ventricular systolic dysfunction. The figure includes patients with prevalent and incident left ventricular systolic dysfunction (LVSD). HCM indicates hypertrophic cardiomyopathy; LVAD, left ventricular assist device; SHaRe, Sarcomeric Human Cardiomyopathy Registry; and Txp, cardiac transplantation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. . 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e533–e557. doi: 10.1161/CIR.0000000000000938 - PubMed
    1. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, et al. ; Authors/Task Force members. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–2779. doi: 10.1093/eurheartj/ehu284 - PubMed
    1. Geske JB, Gersh BJ. The hypertrophic cardiomyopathy paradox: better with age. Eur Heart J. 2019;40:994–996. doi: 10.1093/eurheartj/ehy889 - PubMed
    1. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, et al. . The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647–1655. doi: 10.1056/NEJMoa021715 - PubMed
    1. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, Pereira AC, Ingles J, Semsarian C, Jacoby D, et al. . Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J. 2021;42:1988–1996. doi: 10.1093/eurheartj/ehab148 - PMC - PubMed

Publication types